RankAlpha logo
Back to Rankings

MD

Pediatrix Medical GroupB
NYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
View Chart
Current thesis
Reimbursement, favorable payor mix and acquisitions lifted second-quarter revenue 4.0% and adjusted EBITDA to $76.4 million despite lower patient volume. Sustaining those gains while containing practice costs could support the reaffirmed outlook.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-29 · BMO.
What can break
Higher clinical salaries and malpractice expense pressured same-unit results; revenue-cycle-transition-related costs increased. [#SEC-8K-2026-08-04]
Momentum
74
Value
68
Sentiment
42
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $31.00 · Bear $21.00Analysis 2026-10-10; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-10 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $26.33
Why
Momentum74 · Δ7d +7.6
Value68 · Δ7d -0.2
Sentiment42 · Δ7d -8.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-10-29 · BMO.
  • • Value remains the lead driver in the composite, 7D delta -0.2.

Contradictions & invalidation

  • • Higher clinical salaries and malpractice expense pressured same-unit results; revenue-cycle-transition-related costs increased. [#SEC-8K-2026-08-04]
  • • June 30 cash was $288.9 million against $584 million of debt; cash from continuing operations was below the prior-year quarter. [#SEC-8K-2026-08-04]
  • • Volume declines, rising clinical and malpractice costs, and revenue-cycle transition expense could erode the reimbursement benefit.

Catalyst clock

2026-10-29 · BMO

Test of reaffirmed 2026 EBITDA outlook

Lead driver: Value · See fundamentals
Momentum
74
8% active weight
Current posture
7d trendFlat
Δ7d
+7.6
Δ21d
+10.4
Value
68
47% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
-0.9
Sentiment
42
45% active weight
Current posture
7d trendSoftening
Δ7d
-8.4
Δ21d
-25.4
Why this grade

Composite grade B. Momentum 74.4 / Value 68.0 / Sentiment 42.2

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-10. Scenario method

B+
Bull case
25%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$21.00
Analysis reference price unavailable
Analysis 2026-10-10 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.36B
Beta
0.76
Shares Out
81.25M
P/E (TTM)
11.5
P/S (TTM)
0.98
P/FCF (TTM)
6.88
Rev YoY
+4.0%
EPS YoY
+6.6%
Gross Margin
+25.1%
Op Margin
+12.3%
Net Debt
$134.89M
Current Ratio
1.32
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data